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A B S T R A C T   
Background: While T cell responses to Mycobacterium tuberculosis (Mtb) have been extensively studied, the role of 
B-cells and antibodies are less well characterised. The aim of this study was to assess levels of Mtb-specific IgG +
plasmablasts across the Mtb infection spectrum. 
Methods: Patients with active TB were analysed at baseline and 6 months of therapy (n = 20).Their exposed 
household contacts (HHC) included individuals with latent TB infection (LTBI; n = 20); evident at baseline; 
individuals with a negative Tuberculin Skin Test (TST) at baseline who became; positive at 6 months (converters; 
n = 11) and those who remained negative (non-converters; n = 10). An e x-vivo B-cell ELISPOT was performed to 
analyse plasmablast responses. 
Results: Frequencies of ESAT-6/CFP-10 (EC)- but not Whole Cell Lysate (WCL)-specific plasmablasts were 
significantly higher in patients with active TB pre-treatment compared to post-treatment (p = 0.002) and 
compared to HHC with LTBI (p < 0.0001). Conversely, total IgG + plasmablasts were significantly decreased in 
TB patients at baseline. No difference was seen in levels of plasmablasts between TST converters and non- 
converters at baseline. 
Conclusions: We show that EC-specific plasmablast levels are differentially modulated during TB infection and 
disease, with levels highest during active TB. These data provide new insights into TB biomarker development 
and avenues for novel immune interventions.   
1. Introduction 
Despite the availability of a vaccine and an effective anti-TB therapy, 
TB still remains a major global health problem [1]. The predominant 
contributing factors to the sustained epidemic are lack of a protective 
vaccine, HIV infection, diagnostic difficulties and emergence of multi 
and extensive drug resistant strains of Mycobacterium tuberculosis (Mtb) 
[2]. This resulted in 10 million newly diagnosed cases and 1.5 million 
deaths in HIV negative individuals in 2018 [3]. Interestingly, not all 
individuals exposed to Mtb develop clinical disease. About 90% of 
people will mount a protective immune response that contains the 
infection but rarely eliminates it – termed latent TB infection (LTBI) [4]. 
Approximately one-fourth of the global population are latently infected 
with TB [5], with 5–10% developing active disease in their lifetime [3]. 
Identification of immune subsets protective during different stages of 
Mtb infection and disease is imperative for development of more pro-
tective vaccines [6,7]. Some individuals exposed to Mtb may clear the 
infection through innate immune mechanisms but most require the 
adaptive immune system to contain the infection in granulomas [8]. 
This is predominantly orchestrated by T-cell subsets, mainly T helper 
(Th) 1 [8]. B-cells are also activated leading to the production of 
Mtb-specific antibodies; however, the role of B-cells and antibodies in TB 
immunity is yet to be fully elucidated [9]. 
Since we do not yet know the exact requirements for protective 
immunity to Mtb, it is crucial that previously underappreciated cells are 
evaluated [10]. The change in the frequency of the circulating 
B-lymphocyte repertoire during active TB disease remains controversial: 
some studies have reported either a significant decrease [10–12] or in-
crease [13] of B-cells in the blood of patients with active TB. Data from 
South Africa showed a decrease in proportion of mature B cells from TB 
cases compared to other-lung diseases at diagnosis [10]. A subpopula-
tion of activated memory B cells (CD19 + IgM + CD23 + CD27+) cells 
were found to be present at the end of TB treatment. A study from East 
Africa showed that Mtb-specific memory B-cells (MBCs) to BCG were 
significantly higher in vaccinated compared to unvaccinated individuals 
in Uganda [14]. The same group also showed elevated levels of 
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Mtb-specific plasmablasts (IgG+) in active TB patients despite a reduc-
tion in MBCs compared to healthy and LTBI individuals [15]. Another 
study from Europe showed that patients with active TB had reduced 
circulating B-cell frequencies with impaired proliferation, immuno-
globulin- and cytokine-production. These defects disappeared upon 
successful treatment [16]. Plasmablasts are short-lived plasma cells 
mainly present in the peripheral circulation following an active or 
ongoing infection. A study from Ethiopia demonstrated that circulating 
IgG + plasmablasts and spontaneous secretion of BCG-specific IgG an-
tibodies were significantly higher in patients with active TB compared 
with latent TB cases and non-TB controls [17]. Their study concluded 
that the ratio of plasmablasts and MBCs could be used as a potential 
biomarker to predict clinical status of TB infected individual living in TB 
endemic settings [17]. 
Due to the genetic differences in both host and pathogen in West 
Africa, it is unknown how these findings translate. Thus, the aim of this 
pilot study was to determine the frequency of Mtb-specific and non- 
specific IgG plasmablasts in Mtb infection and disease in a West Afri-
can setting. 
2. Methods 
2.1. Ethics statement 
Ethical approval was obtained from the Medical Research Council/ 
Gambia government joint ethics committee (SCC1333). All study par-
ticipants provided written informed consent for the collection of sam-
ples and subsequent analysis. 
2.2. Study participants 
Twenty (20) GeneXpert and culture positive first episode TB patients 
were analysed pre and post TB treatment (baseline and 6 months). In 
addition, 20 tuberculin skin test (TST) positive (defined as LTBI) 
asymptomatic (assessed by chest x-ray and symptom screening) house-
hold contacts, 11 TST converters (ie TST negative at baseline but TST 
positive at follow-up) and 10 non-converters (TST negative at both time- 
points) were analysed at baseline only. All study participants were HIV 
negative adults. 
2.3. Antigens 
ESAT-6/CFP-10 (EC) fusion proteins were kindly provided by Prof. 
Tom Ottenhoff (Leiden University Medical Center). Whole cell lysate 
(WCL) was obtained from BEI (USA). All antigens were used at a final 
concentration of 10 μg/ml. 
2.4. PBMC isolation, storage and thawing 
Peripheral blood mononuclear cells (PBMCs) were isolated using 
density gradient centrifugation and stored in liquid nitrogen until 
needed. The PBMCs were then removed from liquid nitrogen and semi- 
thawed in a 37 ◦C water bath. The cells were transferred into a 15 ml 
falcon tube containing pre-warmed RPMI (Sigma, UK) +10%FCS 
(Sigma, UK) +200U/ml streptomycin+2 mM L-glutamine (R10) and 
centrifuged at 1500 rpm for 7 min. Following centrifugation, the su-
pernatant was decanted and the cells resuspended in 5 mls R10 + 0.02% 
Benzonase (Sigma, UK) and rested for 5–6 h at 37 ◦C, 5% CO2. After this 
incubation, the cells were washed and resuspended in 2 mls 
R10+Benzonase for counting. 
2.5. Ex-vivo ELISPOT assay 
An ex-vivo B-cell ELISPOT assay was used to determine the fre-
quencies of Mtb-specific plasmablasts. Ninety-six well filter ELISPOT 
plates (Millipore, Germany) were coated overnight with 100 μl of PBS 
containing Mtb-specific proteins. Fragment donkey anti-human IgG (10 
μg/ml) was used as a positive control while wells coated with PBS only 
served as negative controls. Plates were washed and blocked with R10 
for 2 h 200,000 cells were added into the antigen-coated and negative 
control wells in triplicate. For the anti-human IgG coated wells, a 1:200 
dilution of the cell suspension was made and 50 μl was added to the 
ELISPOT plates already containing 150 μl R10 (4000 cells/well final). 
The plates were then incubated at 37 ◦C with 5% CO2 overnight. Plates 
were washed with PBS and incubated with biotin-streptavidin peroxi-
dase-conjugate (Jackson ImmunoResearch, USA) for 2 h. The plates 
were washed again and 100 μl streptavidin- Alkaline-phosphatase 
(1:1000) was added to the plates and incubated for 1 h. Alkaline- 
phosphatase (AP)-conjugate was then added for 10 min in the dark. 
Developed plates were air-dried and the numbers of resultant spots were 
counted on an Autoimmun Diagnostika (AID) ELISPOT plate reader 
(version 7.0). Frequencies of antigen-specific plasmablasts were calcu-
lated automatically and data presented as spot forming units (sfu) per 
million PBMCs. 
2.6. Statistical analysis 
Graph Pad Prism version 7.0 (Software MacKiev, USA) was used for 
the statistical analysis. Prior to analysis, background (Nil) responses 
were subtracted from the stimulated wells. Comparisons of antigen- 
specific PB responses between active TB cases pre-treatment (recruit-
ment) and post-treatment (6-months) and TST + contacts were made 
using the Kruskal-Wallis test followed by Dunn’s post-test comparison. 
Analysis of TB cases pre- and post-treatment was performed using the 
Wilcoxon-matched pairs test. A two tailed T-test was used to analyse 
responses between the converters and non-converters. A p value ≤ 0.05 
was considered significant. 
3. Results 
3.1. Participant demographics 
Participant samples were selected to ensure even distribution of age 
and sex between the groups (Table 1). The median [IQR] range for 
participants with active TB (ATB), latent TB (LTBI), TST converters and 
non-converters was 27[21–42], 28[21–43], 30[23–60] and 22[18–38] 
respectively. The % male in each group was 45, 35, 53 and 50 respec-
tively. All participants were HIV negative. 
3.2. Plasmablast levels in active TB disease compared to LTBI 
In the absence of stimulation (NIL), plasmablast levels were signifi-
cantly higher in TB cases at recruitment compared to 6 months of 
treatment and to LTBI levels (p = 0.0019 and p = 0.0266 respectively; 
Fig. 1). No difference was seen between levels at 6 months of treatment 
and LTBI (Fig. 1). Following EC stimulation (with background subtrac-
tion), plasmablast levels were significantly higher in TB cases at 
recruitment compared to post-treatment and LTBI (p < 0.0001 for both; 
Fig. 1). Again, no statistical difference in EC PB responses was observed 
Table 1 
Participant demographics.   




N = 20 20 11 10 
Age 27[21–42] 28[21–43] 30[23–60] 22[18–38] 
Males (%) 45 35 53 50 
N = number; Age (median[interquartile range]); ATB, active TB; LTBI, latent TB 
infection; TST, tuberculin. 
Skin test; TST converters, TST negative at baseline and positive at 6 months; TST 
non-converters, TST negative at baseline and 6 months. 
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between TB cases after 6-months of therapy and individuals with LTBI. 
There was no difference in responses to WCL nor total IgG between TB 
cases and LTBI at baseline nor for WCL between TB cases at baseline and 
6 months (Fig. 1). However, responses to total IgG were significantly 
higher after 6 months of therapy compared to active TB at baseline (p =
0.0235; Fig. 1). When the ratio of EC-specific to total IgG responses were 
analysed, TB cases at recruitment had a significantly higher ratio 
compared to both cases at 6 months of tx and LTBI (p < 0.0001 for both; 
data not shown). 
3.3. Plasmablast responses in TST converters and non-converters 
TST converters and non-converters were analysed at the baseline 
time-point (prior to conversion). While the median responses to all an-
tigens except EC were higher in the converters, none reached statistical 
significance (Fig. 2A–C). Interestingly, no difference in levels of IgG or 
WCL responses were seen between C, NC and LTBI at baseline but a 
significantly higher level of EC-specific plasmablasts were seen in both C 
and NC at baseline compared to LTBI (p = 0.0115 and p = 0.0014 
respectively; Fig. 2D). 
4. Discussion 
In this study we have shown that peripheral Mtb-specific plasmablast 
responses are differentially modulated at key control points within the 
Mtb infection spectrum. EC-specific PB responses were initially high in 
early infection, reduced in latency, significantly increased during active 
TB disease and reduced following successful TB treatment to LTBI levels. 
The high levels of plasmablasts in patients with active TB, despite an 
overall reduction in total IgG plasmablast levels, is likely due to an in-
crease in mycobacterial loads resulting in preferential expansion of Mtb- 
specific plasmablasts despite a reduction in the total pool available [15]. 
This may also activate Mtb-specific memory B-cells (MBCs), which 
subsequently differentiate into new plasmablast populations, thereby 
contributing to the increased pool of plasmablasts and EC-specific IgG 
antibodies detected within the periphery [18,19]. Our results support 
previous findings that patients with active TB have a dysfunctional 
circulating B-cell population, including impaired proliferation, Ig and 
Fig. 1. Plasmablast responses in active TB cases before and after therapy and in LTBI. Plasmablast responses were analysed following short-term ex-vivo 
ELISPOT. A: background (NIL); B: ESAT-6/CFP-10 (EC); C: Whole Cell Lysate (WCL) and D: Total IgG+ producing cells. Data analysed by Kruskal-Wallis with Dunn’s 
post-test comparison. Box height indicates median. 
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cytokine production, which normalises following TB treatment [20,21]. 
Indeed, we saw a significant decrease in total IgG plasmablasts during 
active TB despite an increase in Mtb-specific levels, which was resolved 
with treatment. 
We have previously shown a predominant B cell signature in in-
dividuals who remained TST negative compared to those who were TST 
negative at baseline but converted to positive at a later time-point [22]. 
This suggested that B cells may play a role in early protection to Mtb 
infection and prompted us to investigate plasmablast levels in these 
same individuals. We found no difference in total IgG or EC-specific 
plasmablast levels at baseline in those who remained TST negative 
(non-converters) compared to those who converted. In contrast to 
findings from Uganda [15] however, levels of EC-specific plasmablasts 
were found to be higher in individuals who were TST negative at 
baseline compared to those who were TST positive (latently infected). 
These results suggest that analysis of other B cell subsets together with 
functionality would be of importance to gauge if B cells and/or anti-
bodies provide a level of protection early in infection. For example, 
differential antibody glycosylation has been shown to occur preferen-
tially on the Fc domain, providing significant discriminatory power 
between different states of M. tuberculosis infection and disease [23]. 
Our results indicate that Mtb-specific plasmablasts may serve as a 
valuable and early diagnostic marker for active TB disease. A memory B- 
cell ELISPOT should also be performed to determine if the plasmablast: 
MBC ratio can distinguish between active and latent TB [15] since PBs 
are significantly higher in active disease while MBCs are higher in latent 
TB infection. Thus, the ratio is more representative of the specific B-cell 
immune response to Mtb since MBCs also contribute to the plasma cell 
pool [15]. 
Taken together, these data demonstrate that peripheral blood B-cell 
responses are differentially modulated during active and latent TB 
infection, and that the frequencies of Mtb-specific PBs in peripheral 
blood may be able to accurately predict the clinical status of Mtb 
infected individuals living in highly TB-endemic regions. These data 
provide new insights into TB biomarker development and avenues for 
novel immune interventions. 
Fig. 2. Plasmablast responses in TST converters (C) and non-converters (NC). Antigen specific PBs were determined by short-term ex-vivo ELISPOT. A: Total IgG; 
B: Whole cell lysate (WCL); C: ESAT-6/CFP-10 (EC) and D: EC stimulation in NC and C compared to LTBI. A-C analysed using Mann-Whitney U-test. D analysed using 
Kruskal-Wallis with Dunn’s post-test comparison. Box height indicates median. 
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